This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors
A Phase 1b/2, Open-Label, Safety, Tolerability And Efficacy Study Of NC410 Plus Pembrolizumab For Participants With Advanced Unresectable And/Or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors Or ICI Naïve MSS/MSI-Low Solid Tumors
To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.